期刊文献+

乳腺癌基因在基底细胞型乳腺癌中的表达及临床意义 被引量:3

Expression of breast cancer 1 in basal-like breast carcinoma and its significance
原文传递
导出
摘要 目的分析乳腺癌基因(BRCA1)在含基底细胞型乳腺癌组织中的表达,并探讨与其预后因素之间的相关性,了解BRCA1对于患者预后的判断价值。方法回顾性分析142例乳腺癌患者的病历资料,66例确诊的三阴性乳腺癌患者为试验组,其他76例患者为对照组。用免疫组化法检测2组患者肿瘤组织中BRCA1的表达,分析BRCA1在试验组和对照组的表达情况、与基底细胞型乳腺癌临床病理特征之间的关系、与p53和Ki67表达的关系。结果 BRCA1在试验组的阳性表达率为72.70%(48/66),显著高于对照组的55.26%(42/76,P<0.05)。BRCA1与年龄、淋巴结转移情况、组织学分级有关(P<0.05),与民族、肿瘤大小、绝经情况无相关性(P>0.05),其与预后因素p53、Ki67之间存在正相关(P<0.05)。结论 BRCA1是反映肿瘤恶性程度的良好指标,其可作为判断基底细胞型乳腺癌预后的指标,为临床个体化治疗提供依据及新的治疗方向。 Objective To analyze the expression of breast cancer 1( BRCA1) in breast cancer basal cell-containing tissues and to explore the correlation between their prognostic factors,in order to determine the value for BRCA1 prognosis.Methods A total of 142 cases of breast cancer patients,66 cases diagnosed with triple negative breast cancer patients as treatment group,76 other patients were in control group.Detected the expression of BRCA1 by immunohistochemistry in two groups,and analyzed the expression in treatment group and control group,the relationship between basal cell carcinoma breast cancer and the clinical pathological features,the relationship between p53 and Ki67 expression also obserived.The positive rate of BRCA1 expression in treatment group was 72.70%( 48 /66),significantly higher than 55.26%in control group( 42 /76,P〈0.05).BRCA1 had positive correlation with age,lymph node metastasis,histological grade( P〈0.05),and had no correlation with nation,tumor size,menopausal status( P〉0.05),had positive correlation with prognostic factors p53,and Ki67( P〈0.05).Conclusion BRCA1 is a good indicator of the degree of malignancy,which could be used as basal cell type breast cancer prognosis,and provide the basis for new therapeutic directions for clinical individualized treatment.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2016年第10期877-879,共3页 The Chinese Journal of Clinical Pharmacology
关键词 乳腺癌 基底细胞型 免疫组织化学 乳腺癌基因 breast cancer basal-like breast cancer immunohistochemistry breast cancer 1
  • 相关文献

参考文献4

  • 1FOULKES W D, STEFANSSON I M, CHAPPUIS P O, et al. Germ- IineBRCA1 mutations and a basal epithelial phenotype in breast cancer[J]. J Natl Cancer Inst,2013,95(19) :1482 - 1485.
  • 2FARMER H,MCCABE N, LORD C J, et al. Targeting the DNA re- pair defect in BRCA1 mutant cells as a therapeutic strategy [ J]. Na- ture ,2005,434 (7035) :917 - 921.
  • 3WOLFF A C, HAMMOND M E, HICKS D G,et al. Recommenda- tions for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oneology/eollege of American pathologists clinical practice guideline update [ J ]. J Clin Oncol, 2013,31 (31) :3997 -4013.
  • 4桑果,王本忠.乳腺癌新辅助化疗不同方案近期疗效观察及化疗前后Ki-67的表达变化[J].安徽医科大学学报,2011,46(11):1181-1184. 被引量:20

二级参考文献9

  • 1格林尼 F L,佩基 D L,弗莱明 I D,等.AJCC癌症分期手册[M].沈阳:辽宁科学技术出版社,2005:99-113.
  • 2Stephen L, Laleh M, Kathy Y, et al. Neoadjuvant therapy for breast cancer[ J]. J Surg Oncol,2010,101 (4) :283 -91.
  • 3Jones R L, Lakhani S, Ring A E, et al. Pathological complete re- sponse and residual DCIS following neoadjuvant chemotherapy for breast carcinoma[ J]. Br J Cancer,2006,94(3 ) :358 -62.
  • 4Taucher S, Steger G G, Jakesz R, et al. The potential risk of neo- adjuvant chemotherapy in breast cancer patients-results from a pro- spective randomized trial of the Austrian Breast and Colorectal Cancer Study Group ( ABCSG-07 ) [ J ]. Breast Cancer Res Treat, 2008,112(2) :309 - 16.
  • 5Shimizu C, Ando M, Kouno T, et al. Current trends and contro- versies over pre-operative chemotherapy for women with operable breast cancer[ J]. Jpn J Clin Oncol,2007,37(1 ): ! -8.
  • 6Sanlglazov V F, Bojok A N, Arsumamv A S, et al. Breast conser- ving surgery after neoadjuvant chemotherapy pactitaxel + doxorubi- cin vs fluorouracil + doxorubicin + cyclophosphamide in locally ad- vanced breast cancer [ J ]. Breast Cancer Res Treat,2002,76 ( Sup- ple 1 ) :52.
  • 7Henderson I C, Berry D, Demetri G D, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubi- cin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer [ J ]. J Clin Oncol, 2003,21 (6) :976.
  • 8Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant do- cetaxel for operable breast cancer induces a high pathological re- sponse and breast-conservation rate [ J ]. Br J Cancer, 2003,88 (9) :1339 -45.
  • 9Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monocolonal antibody reactive with a human nuclear antigen asso- ciate with cell proliferation[J], Int J Cancer, 1983,31 ( 1 ) : 13 - 20.

共引文献19

同被引文献21

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部